Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Betamethasone dipropionate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for betamethasone dipropionate and what is the scope of patent protection?

Betamethasone dipropionate is the generic ingredient in eleven branded drugs marketed by Anda Repository, Fougera Pharms, Glenmark Generics, Perrigo Israel, Taro, Schering, Merck Sharp Dohme, Savage Labs, Acp Nimble, Actavis Mid Atlantic, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Teligent Pharma Inc, Alpharma Us Pharms, Fougera Pharms Inc, Hi Tech, Encore Dermat, Leo Pharma As, Perrigo Uk Finco, Tolmar, and Glenmark Pharms, and is included in sixty-five NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Betamethasone dipropionate has seven patent family members in five countries.

There are sixty-six drug master file entries for betamethasone dipropionate. Twenty-four suppliers are listed for this compound.

Drug Prices for betamethasone dipropionate

See drug prices for betamethasone dipropionate

Drug Sales Revenue Trends for betamethasone dipropionate

See drug sales revenues for betamethasone dipropionate

Recent Clinical Trials for betamethasone dipropionate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Drug Delivery Solutions Ltd. (part of MC2 Therapeutics)Phase 1
Psoriasis Treatment Center of Central New JerseyPhase 4
Celgene CorporationPhase 4

See all betamethasone dipropionate clinical trials

Recent Litigation for betamethasone dipropionate

Identify potential future generic entrants

District Court Litigation
Case NameDate
Promius Pharma LLC v. Perrigo UK FINCO Limited Partnership2018-05-22

See all betamethasone dipropionate litigation

Pharmacology for betamethasone dipropionate
Synonyms for betamethasone dipropionate
(11-beta,16-beta)-9-Chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
(11.beta.,16.beta.)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
(11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
(8S,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-(propionyloxy)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthr
[2-[(8S,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] propanoate
[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
2-((2S,10S,11S,13S,15S,17S,1R,14R)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxo -14-propanoyloxytetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-o xoethyl propanoate
5593-20-4
593B204
826Y60901U
9-Fluoro-11.beta.-hydroxy-16.beta.-methyl-3,20-dioxo-17-(propionyloxy)pregna-1,4-dien-21-yl propionate #
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
9-fluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(propionate)
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17,21-dipropionate
9alpha-Fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 17,21-Dipropionate
9alpha-Fluoro-16beta-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate
AB01274713_02
AB01274713-01
AB01275498-01
AB2000220
AC1L2J44
AC1L3T2H
AKOS015969733
AKOS025312304
Alphatrex
AN-14216
API0001696
B3166
BDBM50421892
Beloderm
beta-Methasone 17,21-dipropionate
Betamethasone 17,21-dipropionate
BETAMETHASONE DIPROP
betamethasone dipropionat
Betamethasone Dipropionate (Diprolene)
Betamethasone dipropionate (JP17/USP)
Betamethasone dipropionate [USAN:BAN:JAN]
Betamethasone dipropionate [USAN:USP:JAN]
betamethasone propionate
Betamethasone-17,21-dipropionate
BRD-K58148589-001-03-6
BRN 3638108
C-22966
C28H37FO7
CAS-5593-20-4
CC-24614
CHEBI:31276
CHEMBL1200384
CIWBQSYVNNPZIQ-XYWKZLDCSA-N
component of Alphatrex (Salt/Mix)
component of Betasone (Salt/Mix)
CS-7549
D01637
Diproderm
Diprolene
Diprolene AF
Diprosis
Diprosone
Diprospan;Diprolene;Diprosone;Diprolene AF;Diprolene
DSSTox_CID_2672
DSSTox_GSID_22672
DSSTox_RID_76683
DTXSID2022672
EBD2157850
EINECS 227-005-2
en-17-yl propionate
FT-0082786
HMS2090K11
HY-13571
Jsp006667
KS-5303
LS-118474
Maxivate
MFCD00133140
MolPort-002-515-791
MolPort-039-145-111
NCGC00159360-02
NCGC00159443-01
NCGC00159443-02
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-.beta.,17,21-trihydroxy-16-.beta.-methyl-,17,21-dipropionate
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-, 17,21-dipropionate
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methyl-,17,21-dipropionate
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11.beta.,16.beta.)-
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)
Psorion
Rinderon DP
Rinderon-DP (TN)
RL03443
S 3440
S-3440
s1688
SC-15701
Sch 11460
Sch-11460
SCHEMBL4566
SCHEMBL7519
Sernivo
Sernivo (TN)
ST024761
Tox21_113343
UNII-826Y60901U
ZINC4212137
Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE
Tradename Dosage Ingredient NDA Submissiondate
SERNIVO SPRAY;TOPICAL betamethasone dipropionate 208079 2018-02-15

US Patents and Regulatory Information for betamethasone dipropionate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 202894-001 Oct 30, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Alpharma Us Pharms BETAMETHASONE DIPROPIONATE betamethasone dipropionate LOTION;TOPICAL 071085-001 Feb 3, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Encore Dermat SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Encore Dermat SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Encore Dermat SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Perrigo New York BETAMETHASONE DIPROPIONATE betamethasone dipropionate LOTION;TOPICAL 072538-001 Jan 31, 1990 AB RX No No   Start Trial   Start Trial   Start Trial
Encore Dermat SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for betamethasone dipropionate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering DIPROLENE betamethasone dipropionate CREAM, AUGMENTED;TOPICAL 019408-001 Jan 31, 1986   Start Trial   Start Trial
Schering DIPROLENE betamethasone dipropionate GEL, AUGMENTED;TOPICAL 019408-002 Nov 22, 1991   Start Trial   Start Trial
Merck Sharp Dohme DIPROLENE betamethasone dipropionate OINTMENT, AUGMENTED;TOPICAL 018741-001 Jul 27, 1983   Start Trial   Start Trial
Merck Sharp Dohme DIPROLENE AF betamethasone dipropionate CREAM, AUGMENTED;TOPICAL 019555-001 Apr 27, 1987   Start Trial   Start Trial
Schering DIPROLENE betamethasone dipropionate CREAM, AUGMENTED;TOPICAL 019408-001 Jan 31, 1986   Start Trial   Start Trial
Merck Sharp Dohme DIPROLENE betamethasone dipropionate LOTION, AUGMENTED;TOPICAL 019716-001 Aug 1, 1988   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
McKinsey
Mallinckrodt
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.